6 / 10
Page 29
Joint Event
November 29-30, 2019 | Frankfurt, Germany
28
th
International Conference on
3
rd
International Conference on
Diabetes and Endocrinology
Diabetes and Metabolism
&
2
0
1
9
CONGRESS
DIABETES
2019
DIABETES
Journal of Diabetology | Volume 3
Notes:
Retrospective real-life efficacy assessment of teneligliptin in Indian T2DM patients
Nikhil S Nasikkar
K J Somiaya Medical College, India
Background:
TeneligliptinisbeenintroducedrecentlyinIndian
market and data available are limited on Indian patients.
Hence, the hospital based real life retrospective evaluation
was planned out to evaluate, the efficacy of teneligliptin in
type 2 diabetes mellitus in Indian population. Hence study
was designed, a retrospective evaluation, of efficacy of
teneligliptin in type 2 diabetes mellitus in Indian population.
Methods:
Data of 11400 patients, who were prescribed
teneligliptin was collected from hospital records. Teneligliptin
20mg was prescribed to all patients who were uncontrolled
on other OHAs and for amean duration of 8weeks. Parameter
evaluated in this study were change in FBG, PPBG and HbA1c
from the baseline at 8week. With profile of outcome i.e.
response and failure rates were also assessed with respect to
age, gender, BMI and duration of diabetes.
Results:
Of 11400 patients were enrolled, 6612 were males
and 4788 females. The average age was 52.77 years among
the study population. The mean duration of diabetes was
23 months. There was significant change in HbA1c, fasting
and postprandial blood glucose levels at 2.55 ±1.88 months
(p=0.001) of teneligliptin therapy. Changes in HbA1c, FPG
and PPG from baseline to end of study were-1.35±1.08%
(p=0.001), -49.01±26.48 mg/dl (p=0.001) and -79.80±32.10
mg/dl (p=0.001) respectively. Out of 11400 patients, 1642
(14.4%) were non-responders where it was further sub
analysed with different parameter such as age, gender, BMI
and duration of diabetes in order to observe response of
teneligliptin in diabetic patients.
Conclusions:
This real life retrospective evaluation showed
efficacy of teneligliptin in real world scenario. It can be an
effective alternative to conventional gliptins available for
prescription in India.
Speaker Biography
Nikhil Sunil Nasikkar is a postgraduate in internal medicine from national
board of examinations, From Bhabha Atomic research centre hospital
MUMBAI. Also a postgraduate in diebetilogy from Annamalai University
Tamilnadu.India. Has experience of diabetes management since last
16 years both inpatient and outpatient . Has publications both national
and international level. Practising as consultant diabetics specialist and
physician in Mumbai. Also working as. Assistant professor in department
of medicine and run the depart of diabetes and endocrine. Currently
working on diabetes and pregnancy with use of flash glucometers. Active
member or RSSDI national body for diabetes research in India. Organising
co secretary 48 th National RSSDI conference in Mumbai Dec 2020.
e:
drniknash@gmail.com